A center focused on immunotherapy for pediatric cancers.
Official title: Pediatric Ohio-New York Cancer (Peds-ONC) Immunotherapy Center
Funded at Research Inst Nationwide Children's Hosp · NIH-9839924 · Data updated 2026-11-12
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Research Inst Nationwide Children's Hosp NIH-funded |
| Lab location | 1 site (Columbus, United States) |
| Project start | September 12, 2019 |
| Project end | August 31, 2025 |
| Funding year | 2019 |
| Award (this year) | $10,242,127 |
| NIH project number | 1U54CA232561-01A1 |
| Project ID | NIH-9839924 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation are children diagnosed with various types of pediatric cancers.
✕Less likely to help
Patients with non-cancerous conditions or those who do not have pediatric cancers may not benefit from this research.
What this research studies
The Pediatric Ohio-New York Cancer (Peds-ONC) Immunotherapy Center aims to develop innovative immunotherapy approaches to treat pediatric cancers by harnessing both innate and adaptive immune responses. This research focuses on overcoming barriers to using natural killer (NK) cells and CAR-NK cells as effective cancer treatments, breaking tolerance to cancer-associated proteins, and enhancing immunotherapies by targeting suppressive immune cells. Patients may benefit from cutting-edge therapies that could improve outcomes for pediatric cancers resistant to conventional treatments.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy options for children with cancer.
How similar studies have gone: Previous research has shown promise in utilizing immunotherapy approaches for pediatric cancers, indicating potential for success in this novel initiative.
Where this research is happening
-
Research Inst Nationwide Children's Hosp
Columbus, United States Active
Researchers
- Principal investigator: Cripe, Timothy P — Research Inst Nationwide Children's Hosp
- Study coordinator: Cripe, Timothy P
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
-
Overcoming obesity-related resistance to immunotherapy in kidney cancer
A study aims to understand why obesity affects how well immunotherapy works for people with advanced kidney cancer and how to improve treatments for those patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.